Cerenome Expands CNSide Coverage to 153 Million Lives with HCSC Deal
Event summary
- Cerenome's CNSide Diagnostics subsidiary signed an in-network agreement with HCSC, effective August 1, 2026.
- The deal expands CNSide® CSF Tumor Cell Enumeration assay coverage to ~153 million commercial and Medicare Advantage lives.
- HCSC operates Blue Cross and Blue Shield plans in five states and offers Medicare Advantage plans in 30 states plus D.C.
- Cerenome exceeded its 2026 full-year objective of 150 million covered lives ahead of schedule.
The big picture
This agreement represents a significant step in Cerenome's strategy to establish broad reimbursement coverage for its diagnostic platform. The deal with HCSC, one of the largest customer-owned health insurers in the U.S., positions CNSide as a key player in cerebrospinal fluid-based diagnostics for cancer patients. The expanded coverage could drive higher test volumes and revenue growth, while potentially setting a new standard for diagnostic access in oncology.
What we're watching
- Adoption Pace
- Whether the expanded coverage will accelerate physician adoption and test utilization.
- Reimbursement Strategy
- How Cerenome will leverage this national platform to drive commercial utilization.
- Competitive Positioning
- The impact of this coverage milestone on CNSide's market differentiation.
Related topics